Katherine Reeder-Hayes, MD, MBA, MSc, described the potential role of real-world evidence as a compliment to clinical trials as well as successful implementation of Big Data for real-world evidence generation.
On Saturday afternoon, the ASCO town hall convened to share different perspectives on administrative burden, pharmacy benefit managers, and clinical pathways.
In a session Saturday morning, Artia Hurria, MD, FASCO, detailed the current state of treatment for older patients with cancer and the reasons why further efforts are needed to improve the evidence base in this population.
James Lin Chen, MD, discussed the various challenges and considerations of enabling precision medicine with health information technology.
A recent review proposes a new form of research that includes cancer researchers as the primary drivers of the process and outlines the benefits of the model in relation to potential improved cost benefits.
Comparative Effectiveness Study Examines Safety, Efficacy of Biosimilar in Clinical Trial, Real-World Practice
The results from a randomized controlled trial were compared with a real-world cohort for the safety and efficacy of a biosimilar to treat chemotherapy-induced neutropenia in patients with breast cancer.
Improvements in life expectancy and quality-adjusted life years as a result of chimeric antigen receptor T-cell therapy is dependent upon immediate access to treatment.
A new study attempted to quantify the economic burden of early progression in patients with newly-diagnosed multiple myeloma.
A recent systematic review evaluated whether survivorship care plan delivery has a positive impact on health outcomes and health care delivery for patients with cancer.
A new study examined post-treatment evaluation methods of head and neck squamous cell carcinoma in the context of advanced imaging and value-based care.